Log in

Oxford BioMedica Share Price, Forecast & Analysis (LON:OXB)

GBX 568
+13.00 (+2.34 %)
(As of 11/20/2019 01:31 AM ET)
Today's Range
550
Now: GBX 568
571
50-Day Range
499
MA: GBX 545.86
570
52-Week Range
461.50
Now: GBX 568
793
Volume34,806 shs
Average Volume6.89 million shs
Market Capitalization£436.05 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments. Read More…

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1865-783000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£63.59 million
Cash FlowGBX 34.36 per share
Book ValueGBX 104.50 per share

Profitability

Miscellaneous

Employees432
Market Cap£436.05 million
Next Earnings DateN/A
OptionableNot Optionable

Receive OXB News and Ratings via Email

Sign-up to receive the latest news and ratings for OXB and its competitors with MarketBeat's FREE daily newsletter.


Oxford BioMedica (LON:OXB) Frequently Asked Questions

What is Oxford BioMedica's stock symbol?

Oxford BioMedica trades on the London Stock Exchange (LON) under the ticker symbol "OXB."

What price target have analysts set for OXB?

3 equities research analysts have issued 1-year price targets for Oxford BioMedica's shares. Their forecasts range from GBX 810 to GBX 810. On average, they anticipate Oxford BioMedica's stock price to reach GBX 810 in the next twelve months. This suggests a possible upside of 42.6% from the stock's current price. View Analyst Price Targets for Oxford BioMedica.

What is the consensus analysts' recommendation for Oxford BioMedica?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford BioMedica in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oxford BioMedica.

Has Oxford BioMedica been receiving favorable news coverage?

News headlines about OXB stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Oxford BioMedica earned a news impact score of 1.5 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Oxford BioMedica.

Who are some of Oxford BioMedica's key competitors?

What other stocks do shareholders of Oxford BioMedica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford BioMedica investors own include Enquest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Afren (AFR), Premier Oil (PMO), Barclays (BARC), Genel Energy (GENL) and Andalas Energy and Power (ADL).

Who are Oxford BioMedica's key executives?

Oxford BioMedica's management team includes the folowing people:
  • Mr. John Dawson, CEO & Exec. Director (Age 59)
  • Mr. Stuart Paynter, CFO & Director
  • Mr. Timothy William Watts, Exec. Officer (Age 61)
  • Mr. Peter Nolan, Consultant (Age 66)
  • Mr. Nick Page, Chief Operations Officer

How do I buy shares of Oxford BioMedica?

Shares of OXB and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Oxford BioMedica's stock price today?

One share of OXB stock can currently be purchased for approximately GBX 568.

How big of a company is Oxford BioMedica?

Oxford BioMedica has a market capitalization of £436.05 million and generates £63.59 million in revenue each year. Oxford BioMedica employs 432 workers across the globe.View Additional Information About Oxford BioMedica.

What is Oxford BioMedica's official website?

The official website for Oxford BioMedica is http://www.oxfordbiomedica.co.uk/.

How can I contact Oxford BioMedica?

Oxford BioMedica's mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The biopharmaceutical company can be reached via phone at +44-1865-783000.


MarketBeat Community Rating for Oxford BioMedica (LON OXB)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  284 (Vote Outperform)
Underperform Votes:  325 (Vote Underperform)
Total Votes:  609
MarketBeat's community ratings are surveys of what our community members think about Oxford BioMedica and other stocks. Vote "Outperform" if you believe OXB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel